Articles

  • 1 week ago | insideprecisionmedicine.com | Chris Anderson

    New research from the Columbia Mailman School of Public Health shows that adults in the U.S. with both hypertension and type 2 diabetes (T2D) face a much higher risk or all-cause mortality and as a three times higher cardiovascular risk of mortality than those people with only one, or neither of these conditions.

  • 1 week ago | insideprecisionmedicine.com | Chris Anderson

    Researchers at Josep Carreras Leukaemia Research Institute and Hospital 12 de Octubre in Spain have tested a new CAR-T immunotherapy that can effectively maintain its treatment efficacy longer in B-cell acute lymphoblastic leukemia (B-ALL) versus current therapies. This new approach, which targeted the CD19 protein, is the latest advance in improving therapeutic response for patients who have relapsed or did do not respond to current standard treatments.

  • 1 week ago | insideprecisionmedicine.com | Chris Anderson

    The oral drug lamivudine, originally approved for HIV treatment, was shown to significantly improve visual acuity in patients with center-involved diabetic macular edema (CI-DME), a leading cause of vision loss in adults with diabetes. The finding, published in the Cell journal Med, could offer a less invasive alternative approach to current therapies that involve intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents.

  • 1 week ago | insideprecisionmedicine.com | Chris Anderson

    A new retrospective study by researchers at the Department of Clinical Laboratory at the Second Affiliated Hospital of Nanchang University, China has shown that the high-throughput sequencing method called metagenomic next-generation sequencing (mNGS) can detect more than three times as many pathogens in pulmonary infections as conventional microbiological tests (CMTs).

  • 2 weeks ago | insideprecisionmedicine.com | Chris Anderson

    An integration of large-scale datasets across species and methods by a team of researchers from MIT and Harvard Medical School has identified potential new drug targets for Alzheimer’s disease (AD) that look to address other aspects of the disease beyond the most prevalent focus on amyloid plaques.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →